Skip to main content
SpringerLink
Log in

Chemotherapieinduzierte Veränderungen bei hochmalignen zentralen Osteosarkomen

Erfahrungen aus der referenzpathologischen Tätigkeit in den COSS-Studien

Chemotherapy-induced changes in highgrade central osteosarcomas—experiences gained through the assignment as reference-pathologists of the COSS-studies

  • Schwerpunkt: Tumorregression
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Hochmaligne zentrale Osteosarkome sind die häufigsten malignen Knochentumoren im Kindes- und Jugendlichenalter. Die Prognose konnte durch die neoadjuvante Chemotherapie deutlich verbessert werden. Die morphologische Auswertung der chirurgischen Resektionspräparate ergibt wichtige Aussagen über den Therapieerfolg. Der histologisch bestimmte Regressionsgrad stellt einen der bedeutendsten, therapieabhängigen Prognosefaktor beim Osteosarkom dar. Der pathologisch-anatomischen Analyse der Operationspräparate kommt auch unter den Bedingungen einer verbesserten klinischen und radiologischen Diagnostik beim Osteosarkom weiterhin eine hohe Bedeutung zu.

Abstract

High-grade central osteosarcomas are the most frequent malignant bone neoplasms in childhood and adolescence. Their prognosis has been substantially improved using neoadjuvant chemotherapy. The morphological examination of surgical specimens reveals important information regarding the success of treatment. The histological determined degree of regression represents one of the most reliable therapy-related prognostical factor. Thus pathological analysis of the surgical specimens is of great importance notwithstanding the improved clinical and radiological diagnostic of osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8

Literatur

  1. Bielack S (2002) Das Osteosarkom: Therapie und Prognose—Erfahrungen aus zwei Jahrzehnten interdisziplinärer, multizentrischer Zusammenarbeit. Pabst Sciences, Berlin Bremen Riga Rom Viernheim Wien Zagreb

    Google Scholar 

  2. Bielack SS, Kempf-Bielack B, Schwenzer D et al. (1999) Neodajuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten. Klin Paediatr 211:260–270

    CAS  Google Scholar 

  3. Bielack S, Kempf-Bielack B, Delling G et al. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 20:776–790

    Article  PubMed  Google Scholar 

  4. Bieling P, Rehan N, Winkler P et al. (1996) Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14:848–858

    CAS  PubMed  Google Scholar 

  5. Bodey B, Gröger AM, Bodey B Jr et al. (1997) Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17:493–498

    CAS  PubMed  Google Scholar 

  6. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V (1997) P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706–1715

    Article  CAS  PubMed  Google Scholar 

  7. Davis AM, Bell RS, Goodwin P J (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431

    Google Scholar 

  8. Delling G, Dreyer T, Heise U et al. (1990) Therapieinduzierte Veränderungen in Osteosarkomen—qualitative und quantitative morphologische Ergebnisse der Therapiestudie COSS 80 und ihre Beziehung zur Prognose. Tumordiagn Ther 11:167–174

    Google Scholar 

  9. Delling G, Winkler K, Heise U, Salzer-Kuntschik M (1989) Quantitative analysis of tumour regression and distribution of viable tumour areas in osteosarcomas following polychemotherapy. Med Pediatr Oncol 17:305

    Google Scholar 

  10. Enneking WF (1989) Musculoskeletal tumor staging: 1988 update. Cancer Treat Res 44:39–49

    CAS  PubMed  Google Scholar 

  11. Fellenberg J, Krauthoff A, Pollandt K et al. (2004) Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 84:113–121

    Article  PubMed  Google Scholar 

  12. Fuchs N, Bielack SS, Epler D et al. (1998) Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9:893–899

    Article  CAS  PubMed  Google Scholar 

  13. Glasser DB, Lane JM, Huvos AG (1992) Survival, prognosis, and therapeutic response in osteogenic sarcoma. Cancer 69:698–708

    CAS  PubMed  Google Scholar 

  14. Gorlick R, Huvos AG, Heller G et al. (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781–2788

    CAS  PubMed  Google Scholar 

  15. Grimer RJ, Carter SR, Tillman RM et al. (1999) Osteosarcoma of the pelvis. J Bone Joint Surg Br 81:796–802

    Article  CAS  PubMed  Google Scholar 

  16. Kager L, Zoubek A, Potschger U et al. (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21:2011–2018

    Article  PubMed  Google Scholar 

  17. Kawai A, Huvos AG, Meyers PA, Healey JH (1998) Osteosarcoma of the pelvis—Oncologic results of 40 patients. Clin Orthop 348:196–207

    PubMed  Google Scholar 

  18. Kempf-Bielack B, Bielack S, Bieling P et al. (1996) Local failure (LF) of osteosarcoma (OS): risk factors and prognosis. Results of the cooperative osteosarcoma study group. Proc Am Soc Clin Oncol 15:A1674

    Google Scholar 

  19. Kempf-Bielack B, Epler D, Winkler K, Bielack S (1998) Primary osseous spread of osteosacoma—bad news?! Acta Orthop Scand 68 (Suppl 276):61

    Google Scholar 

  20. Kilpatrick SE, Geisinger KR, King TS et al. (2001) Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14:1277–1283

    Article  CAS  PubMed  Google Scholar 

  21. Oliveira P, Nogueira M, Pinto A, Almeida MO (1997) Analysis of p53 expression in osteosarcoma at the jaw: correlation with clinicopathologic and DNA ploidy findings. Hum Pathol 28:1361–1365

    CAS  PubMed  Google Scholar 

  22. Picci P, Bacci G, Campanacci M et al. (1985) Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56:1515–1521

    CAS  PubMed  Google Scholar 

  23. Picci P, Sangiorgi L, Rougraff BT et al. (1994) Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 12:2699–2705

    Google Scholar 

  24. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R (1983) Morphological grades of regression in osteosarcoma after polychemotherapy—COSS 80 study. J Cancer Res Clin Oncol Suppl 106:21–24

    Google Scholar 

  25. Scholz RB, Horstmann M, Werner M et al. (1997) Pattern of gene alterations in osteosarcoma: RB1, p53, DCC, MDM 2, and SAS. Acta Orthop Scand Suppl 276:68

    Google Scholar 

  26. Scholz RB, Kabisch H, Weber B et al. (1992) Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 9:125–137

    CAS  PubMed  Google Scholar 

  27. Scotlandi K, Serra M, Nicoletti G et al. (1996) Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56:2434–2439

    CAS  PubMed  Google Scholar 

  28. Werner M, Fuchs N, Salzer-Kuntschik M et al. (1996) Therapie-induzierte Veränderungen an Osteosarkomen nach neoadjuvanter Chemotherapie (Therapiestudie COSS86). Beziehungen zwischen morphologischen Befunden und klinischem Verlauf. Pathologe 17:35–43

    Article  CAS  PubMed  Google Scholar 

  29. Werner M, Heintz A, Delling G (1997) Beziehungen zwischen DNA-Ploidie-Muster und Chemotherapie-induzierter Tumorregression bei Osteosarkomen. Verh Dtsch Ges Pathol 81:672

    Google Scholar 

  30. Winkler K, Beron G, Delling G et al. (1988) Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS 82) with salvage chemotherapy bases on histological tumor response. J Clin Oncol 6:329–337

    CAS  PubMed  Google Scholar 

  31. Winkler K, Beron G, Kotz R et al. (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative german/austrian study. J Clin Oncol 2:617–624

    CAS  PubMed  Google Scholar 

  32. Winkler K, Bielack S, Delling G et al. (1993) Treatment of osteosarcoma: experience of the cooperative osteosarcoma study group (COSS). In: Humphrey GB (ed) Osteosarcoma in adolescents and young adults. Kluwer, Boston

  33. Winkler K, Bielack S, Delling G et al. (1993) Treatment of osteosarcoma: experience of the cooperative osteosarcoma study group (COSS). Cancer Treat Res 62:269–277

    CAS  PubMed  Google Scholar 

  34. Wunder JS, Bull SB, Aneliunas V et al. (2000) MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18:2685–2694

    CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Institut für Osteopathologie, Universitätsklinikum Hamburg-Eppendorf

    M. Werner & G. Delling

  2. Institut für Osteopathologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg

    M. Werner

Authors
  1. M. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Delling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Werner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Werner, M., Delling, G. Chemotherapieinduzierte Veränderungen bei hochmalignen zentralen Osteosarkomen. Pathologe 25, 445–454 (2004). https://doi.org/10.1007/s00292-004-0712-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-004-0712-7

Schlüsselwörter

Keywords

Search

Navigation